Our lead pipeline product is IBI-10090 which is being developed as a sustained-released therapy for inflammation associated with cataract surgery. An estimated 3 million or more cataract surgeries are performed annually in the U.S. alone.

This product employs Icon’s Verisome drug delivery platform to dispense a long-acting, biodegradable formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following surgery. IBI-10090 has been specifically designed to deliver a controlled release of the active agent over a sufficient time to provide an alternative to the current standard treatment regimen involving a comparatively burdensome process of patient administered eye drops applied topically several times daily for an extended period of time.

IBI-10090 is well advanced into a pivotal Phase 3 randomized, double blind, and placebo-controlled study.  A previous Phase 2/3 study demonstrated a favorable efficacy and safety profile.

More information can be found on clinicaltrials.gov.



My Canadian Pharmacy is an informative service. All the information should not be used in the purposes to establish a diagnosis and prescribe a treatment plan. Our company is a vendor, not a drug manufacturer. We cooperate with drug manufacturers who distribute their products to us. We have no relation with Icon Bioscience and Verisome. They move to another domain. We bear no responsibility for any damage brought to your health. All the questions related to the drug quality should be addressed to the drug manufacturer directly.